A5072027018- Liver Disease Diagnosis and Treatment
- Folate and B Vitamins Research
- Liver Disease and Transplantation
- Diet, Metabolism, and Disease
- Blood Pressure and Hypertension Studies
- Healthcare Systems and Technology
- Cardiovascular Function and Risk Factors
- Primary Care and Health Outcomes
- Pharmaceutical studies and practices
- Metabolism, Diabetes, and Cancer
- Clinical practice guidelines implementation
- Congenital Heart Disease Studies
- Pharmaceutical Practices and Patient Outcomes
- Alcohol Consumption and Health Effects
- Electronic Health Records Systems
- Pain Management and Opioid Use
- Pituitary Gland Disorders and Treatments
- Health and Well-being Studies
- Adrenal and Paraganglionic Tumors
- Respiratory Support and Mechanisms
- Cardiovascular Disease and Adiposity
- Heart Rate Variability and Autonomic Control
- Hormonal Regulation and Hypertension
- Bariatric Surgery and Outcomes
- Chronic Disease Management Strategies
University of Florida
2016-2024
Florida College
2020-2023
Research Triangle Park Foundation
2023
General Department of Preventive Medicine
2020
The cut-off point of intrahepatic triglyceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magnetic resonance spectroscopy (1 H-MRS) was established based on the 95th percentile in a group healthy individuals (i.e., ≥5.56%). Whether this threshold correlates with metabolic and histological changes whether further accumulation IHTG is associated worsening these parameters has not been properly assessed large cohort patients. In cross-sectional study, 352...
Pharmacogenetic testing (PGT) is increasingly being used as a tool to guide clinical decisions. This article describes the development of an outpatient, pharmacist-led, pharmacogenetics consult clinic within internal medicine, its workflow, and early results, along with successes challenges. A pharmacogenetics-trained pharmacist encouraged primary care physicians (PCPs) refer patients who were experiencing side effects/ineffectiveness from certain antidepressants, opioids, and/or proton pump...
DiGeorge syndrome (DGS) is caused by a chromosomal microdeletion at 22q11.2 that results in impaired development of the pharyngeal pouch system. Patients with DGS may have developmental abnormalities craniofacial structures, parathyroid glands, thymus and cardiac outflow tract. Doctors been routinely testing for newborns conotruncal anomalies since late 1990s; before then, however, they relied on complex diagnostic criteria disease was often missed. Adults born defects 1990s undiagnosed DGS....
Prolonged hospitalizations have contributed to the concentration of American healthcare spending in a small subset patients. Research related such events is scarce. The authors performed retrospective analysis at tertiary care center between 2012 and 2022. Extensively prolonged hospitalization (EPH) was defined as an uninterrupted hospital stay least 183 days. Patient data, including past medical history, complications, barriers discharge, long-term outcomes were collected. Among 393,474...
Background.Along with the global prevalence of obesity, associated health and economic impacts are rapidly multiplying.The challenge to primary care is identify treat obesity as a chronic disease.Patients should receive specific advice about diet, lifestyle, physical activity rather than vague or terse recommendation simply eat less exercise.Regular monitoring follow-up visits critical, any disease.When nonpharmacologic methods do not lead weight loss, select patients be offered...
Nonalcoholic steatohepatitis (NASH) is a leading cause of cirrhosis. Diagnosis remains challenging as liver biopsy usually not feasible. NIS4 novel plasma diagnostic test combining the measurement A1c and 3 biomarkers (miR-34a-5p, A2M, YKL-40) linked to NASH disease activity higher cirrhosis risk. The aim this study was assess prevalence high-risk (NASH with significant fibrosis [≥F2]) estimated by or elastography in outpatient setting. A total 400 participants (age: 55±11 years; BMI:...
Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent in the general population with multiple known metabolic risk factors. There limited evidence on impact of age prevalence hepatic steatosis and fibrosis, their relationship to cardiometabolic To this end, we recruited 761 patients 35-75 years age, without T2DM, who underwent screening for NAFLD laboratory tests imaging by elastography (steatosis controlled attenuation parameter [CAP]; fibrosis stiffness measurement...
The prevalence of young-onset type 2 diabetes mellitus (YOT2DM), defined as T2DM diagnosed in adults <45 years old, is steadily increasing. Nonalcoholic fatty liver disease (NAFLD) common people with but its YOT2DM unknown. We therefore hypothesized that NAFLD an emerging health concern this population. A total 161 aged 35-44 and without T2DM, underwent screening for laboratory tests imaging by elastography (steatosis controlled attenuation parameter [CAP]; fibrosis stiffness...